Summit Therapeutics Inc. Research and Development Expense (Excluding Acquired in Process Cost)
Summit Therapeutics Inc. (SMMT) reported Research and Development Expense (Excluding Acquired in Process Cost) of $537.67 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost · last filed 2026-02-23
- Summit Therapeutics Inc. research and development expense (excluding acquired in process cost) for the quarter ending 2025-12-31 was $147.29M, a 186.66% increase year-over-year.
- Summit Therapeutics Inc. research and development expense (excluding acquired in process cost) for the quarter ending 2025-09-30 was $131.10M, a 247.51% increase year-over-year.
- Summit Therapeutics Inc. research and development expense (excluding acquired in process cost) for the quarter ending 2025-06-30 was $208.02M, a 575.44% increase year-over-year.
- Summit Therapeutics Inc. research and development expense (excluding acquired in process cost) for the quarter ending 2025-03-31 was $51.27M, a 66.05% increase year-over-year.
- Summit Therapeutics Inc. research and development expense (excluding acquired in process cost) for fiscal 2025 was $537.67M, a 256.60% increase from fiscal 2024.
- Summit Therapeutics Inc. research and development expense (excluding acquired in process cost) for fiscal 2024 was $150.78M, a 153.53% increase from fiscal 2023.
- Summit Therapeutics Inc. research and development expense (excluding acquired in process cost) for fiscal 2023 was $59.47M, a 14.37% increase from fiscal 2022.
- Summit Therapeutics Inc. research and development expense (excluding acquired in process cost) for fiscal 2022 was $52.00M.
| Period end | Research and Development Expense (Excluding Acquired in Process Cost) 3 month | Research and Development Expense (Excluding Acquired in Process Cost) 6 month | Research and Development Expense (Excluding Acquired in Process Cost) 9 month | Research and Development Expense (Excluding Acquired in Process Cost) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $147.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $278.39M derived: sum of 2 quarters · filed 2026-02-23 | $486.41M derived: sum of 3 quarters · filed 2026-02-23 | $537.67M 10-K · filed 2026-02-23 |
| 2025-09-30 | $131.10M 10-Q · filed 2025-10-20 | $339.12M derived: sum of 2 quarters · filed 2025-10-20 | $390.38M 10-Q · filed 2025-10-20 | $441.76M derived: sum of 4 quarters · filed 2026-02-23 |
| 2025-06-30 | $208.02M 10-Q · filed 2025-08-11 | $259.29M 10-Q · filed 2025-08-11 | $310.67M derived: sum of 3 quarters · filed 2026-02-23 | $348.39M derived: sum of 4 quarters · filed 2026-02-23 |
| 2025-03-31 | $51.27M 10-Q · filed 2025-05-01 | $102.65M derived: sum of 2 quarters · filed 2026-02-23 | $140.37M derived: sum of 3 quarters · filed 2026-02-23 | $171.17M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-12-31 | $51.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $89.11M derived: sum of 2 quarters · filed 2026-02-23 | $119.90M derived: sum of 3 quarters · filed 2026-02-23 | $150.78M 10-K · filed 2026-02-23 |
| 2024-09-30 | $37.72M 10-Q · filed 2025-10-20 | $68.52M derived: sum of 2 quarters · filed 2025-10-20 | $99.39M 10-Q · filed 2025-10-20 | $124.21M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $30.80M 10-Q · filed 2025-08-11 | $61.67M 10-Q · filed 2025-08-11 | $86.48M derived: sum of 3 quarters · filed 2026-02-23 | $101.81M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $30.87M 10-Q · filed 2025-05-01 | $55.69M derived: sum of 2 quarters · filed 2026-02-23 | $71.01M derived: sum of 3 quarters · filed 2026-02-23 | $80.46M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $24.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $40.14M derived: sum of 2 quarters · filed 2026-02-23 | $49.59M derived: sum of 3 quarters · filed 2026-02-23 | $59.47M 10-K · filed 2026-02-23 |
| 2023-09-30 | $15.32M 10-Q · filed 2024-10-30 | $24.77M derived: sum of 2 quarters · filed 2024-10-30 | $34.66M 10-Q · filed 2024-10-30 | |
| 2023-06-30 | $9.45M 10-Q · filed 2024-08-06 | $19.33M 10-Q · filed 2024-08-06 | ||
| 2022-12-31 | $52.00M 10-K · filed 2025-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |